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Summary 
This commentary introduces a new clinical trial construct, the Master Observational Trial (MOT), 
which hybridizes the power of molecularly based master interventional protocols with the breadth of 
real-world data. The MOT provides a clinical venue to allow molecular medicine to rapidly advance, 
answers questions that traditional interventional trials generally do not address, and seamlessly 
integrates with interventional trials in both diagnostic and therapeutic arenas. The result is a more 
comprehensive data collection ecosystem in precision medicine. 
Keywords 
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Introduction 
Advances in basic science allow a deeper understanding of the cellular underpinnings of disease. 
Without clinical correlation, however, many of these molecular techniques take decades to translate 
into improved patient care. The interplay of genomes, transcriptomes, proteomes, metabolomes, 
epigenomes, cellular metabolism, microenvironment, immune characteristics, gut biome, and other 
factors steadily increases the complexity in understanding how everything fits together. One of the 
largest impediments to the advancing of molecular medicine is the clinical infrastructure to allow 
exploration, validation, and implementation of the tools needed to turn precision testing into 
personalized treatment. (Subbiah and Kurzrock, 2018). 
Molecularly Based Interventional Trials 
The majority of what we know in precision medicine has come from clinical trials centered on 
specific alterations that directly impact either disease prognosis or treatment decisions. These 
interventional trials mitigate bias by fixing as many variables as possible, such as selecting patients 
that meet certain criteria, limiting testing to selected laboratories or methods, defining the threshold 
of testing results that trigger treatment, limiting treatment to one point in time in the patient journey, 
and, in some cases, randomization of patients. Biomarker data are integrated into the trial design 
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and captured as part of the trial. The result is a scientifically stringent glimpse of a specific type of 
patient at a specific point in time: tested, treated, followed-up, and reported using precise rules. 
Regulatory agencies, such as the United States Food and Drug Administration (FDA), consider 
interventional trials tied to defined molecular testing as the gold standard for data collection in 
precision medicine. These trials advance clinical practice through identification of testing and 
treatments that can be applied to defined patients.  
 
Master interventional protocols are an important evolution of traditional interventional trials. By 
using a common testing method, unified protocol, and shared infrastructure, multiple single arm 
trials tied to specific biomarkers can run in parallel. Arms can be opened and closed as information 
is gained (Woodcock and LaVange, 2017).  
Challenges of Molecularly Based Interventional Trials 
Interventional trials are generally sponsored by groups who want to answer specific questions that 
will allow regulatory bodies to evaluate the benefit of a distinct intervention. One of the most 
ambitious and comprehensive interventional master protocols in oncology is the National Cancer 
Institute’s Molecular Analysis for Therapy Choice Trial (NCI-MATCH). In a 2017 poster update, NCI-
MATCH had screened close to 6,000 patients with 18% of patients harboring an alteration that 
would allow them to be included in a treatment arm of the protocol. At that reporting, 8 of 30 arms 
had enrolled the minimum patient number to meet the scientific threshold. Patients in these arms 
were scattered across all tumor types. Like most other interventional trials, MATCH is focusing on 
the therapeutic advantage of a treatment in patients with certain biomarker profiles (Harris, L. et. al., 
2017). MATCH is extremely valuable to advance precision medicine but has not been designed to 
provide comprehensive answers. In addition, it is unclear how a typical trial patient would compare 
to a patient in the real world (Dear et al., 2017; Kennedy-Martin et al., 2015). Interventional trials 
usually focus on narrow molecular signatures and only one line of therapy. 
 
Interventional trials are a specific tool for a specific purpose—akin to finding a single piece of a 
large jigsaw puzzle, where personalized medicine represents the entire completed puzzle. Ideally, if 
we could run enough interventional trials and integrate all data into one source, we could eventually 
piece together a comprehensive understanding of personalized care. However, due to cost, 
complexity, market forces, and other factors, it is extremely unlikely that we will ever build a 
comprehensive model of any disease using interventional trials alone. 
Real-world Data (RWD) with Molecular Annotation 
Real-world data can be defined as any information to help advance patient care that comes from 
sources other than traditional clinical trials. Sources may include electronic medical records, mobile 
devices, insurance claims, and disease registries. Analysis of this data generates real-world evidence 
that, in turn, can generate meaningful insights into unmet needs, interventional pathways, and the 
clinical and economic impact on patients and healthcare systems. The FDA has recognized that RWD 
of sufficient quality may provide a better snapshot of how an intervention impacts a broader patient 
population. The hope is that RWD, because of its plentiful nature, can be used to fill knowledge 
gaps that exist between limited number of patients in clinical trial scenarios and the vast number of 
patients in the actual practice of medicine (Booth and Tannock, 2014; Sherman et al., 2016). The 
FDA evaluates the quality of RWD on the basis of how well the data collection effort negates bias.  
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RWD is most commonly obtained retrospectively from electronic health records (EHR), charts, and 
claims information. Focused efforts, such as retrospective observational trials, can improve data 
collection reliability. These efforts generally limit their purview to defined sets of patients with a 
certain biomarker signature at a specified time point. 
 
Prospective observational trials employ many of the same methods as interventional trials to 
mitigate bias. Some of these include written protocols, screened patient populations (although, 
generally not to the degree of an interventional trial), prescribed testing (although, often not limited 
to one specific method), standardized reporting, consistent reassessment intervals, and unified 
training. Molecular testing data that are collected from these studies often focus on a limited 
number of biomarkers with the results of different laboratories being lumped together. Frequently, 
only a certain point of time in the treatment is collected.  
Challenges of Molecularly Based RWD 
Most RWD is collected retrospectively. Data from these sources is frequently non-standardized, 
incomplete, inconsistent, non-accessible, siloed, and may still harbor biases that are not 
ameliorated by large sample size (Berger et al., 2016; Kaplan et al., 2014). Complete biomarker 
data is usually not present. The heterogeneity of both inter-physician and intra-physician care can 
introduce bias even when a formal retrospective analysis identifies a pre-defined outcome in the 
reviewed records. The notations in the electronic medical records may be confusing, contradictory, 
incomplete, and/or difficult to interpret.  
 
Adding molecular annotation to retrospective RWD, especially in oncology, creates additional 
complexity in areas such as: 
1) Equivalence: The equivalence between different testing methods for the same biomarkers is 
largely unknown. There may be analytical differences even with similar methods on similar 
specimens and/or a lack of clinical data identifying best practices (if any) of one testing type 
or testing tissue as compared to another. (Aggarwal et al., 2018; Stetson et al., 2019).  
2) Interpretation: The complexity of molecular analysis and its clinical application has created 
significant variability in testing and reporting. To try to limit this variability, professional 
societies continue to issue guidance, but these recommendations usually are in response to 
gaining experience with the test and a body of information from which recommendations can 
take place. For example, testing for the human epidermal growth factor receptor-2 (HER2) in 
breast cancer was initially approved along with the drug trastuzumab in 1998, and yet the 
last major update on the best methods to test for HER2 was updated in 2013. (Wolff et al., 
2013). Further, we are still in the early stages of understanding how to use powerful new 
technologies such as next-generation sequencing. (Jennings et al., 2017; Roy et al., 2018). 
On the clinical side, identical biomarker profiles can be interpreted differently by different 
physicians, leading to different treatment even with the same findings. (Rieke et al., 2018). 
3) Recording: The source of much biomarker data in RWD comes through reports in the 
medical record. Frequently, molecular testing is performed in outside laboratories 
independent of the ordering physician. Results of this testing are often entered into the 
electronic health record in analog format (i.e., paper document scanned into record or PDF). 
Unless a research group has direct access to digital formats of laboratory results and clinical 
data, molecularly annotated RWD from the EHR is not easily captured. In addition, when 
results are included in clinical records, they are often qualitatively summarized as being 
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positive or negative without discussing details such as testing method, laboratory, or any 
crucial quantitative information.  
The Evidentiary Gap in Personalized Medicine 
Unraveling the molecular conundrum of disease requires a more comprehensive understanding of 
smaller subsets of patients segregated by cellular processes, and a fuller understanding of how 
these subsets relate to each other. This quest requires several principles to come together: 
1) Precise classification of broad molecular signatures; 
2) Standardized clinical elements longitudinally tied to molecular data; 
3) Sufficient quantity of quality data to allow scientific comparison between groups; 
4) The ability to analyze and review complex datasets; and,  
5) The mechanism to evolve interventions as new information is learned. 
The evidentiary gap in precision medicine lies between the data from the narrowly focused low-
quantity, high-quality interventional studies and lower-quality but plentiful RWD. At the current time, 
neither interventional data nor RWD can fulfill the five criteria listed above. 
The Master Observational Trial (MOT) as a Solution 
In order to fill the gap that exists in data collection in precision medicine and fulfill the requirements 
for a comprehensive strategy, we propose a new class of clinical master protocol: the Master 
Observational Trial. The MOT is an amalgamation of master interventional trials, prospective 
observational trials, and a precise method of cataloging molecular data (the Molecular Matrix) (see 
Figure 1A). 
The General Structure of an MOT 
The MOT is a prospective, observational trial that broadly accepts patients independent of 
biomarker signature and collects comprehensive data on each.  
MOTs will likely have the following common characteristics: 
 
1) Transparent governance. Multi-institutional and international efforts are essential in the 
designing and implementing of an MOT. Leadership must transparently address cross-
institutional and cross-stakeholder concerns to bring groups together, especially across borders 
where practice settings and data collection regulations are different. 
2) Centralized trial administrative functions. These provide organizational consistency across 
institutions and include central leadership, contracting, institutional review board (IRB), training 
and certification, and audit. 
3) Traditional interventional trial organization. This helps mitigate bias by standardizing as 
much as possible and includes a written and registered protocol, standardized case-report 
forms, defined reporting, and regular queries for missing or unclear data. 
4) IRB approved patient consent and HIPAA (or equivalent) privacy authorization. These 
important elements of the MOT are developed country by country to comply with data privacy 
regulations, allow for deeper data collection on certain patients in order to answer specific 
questions, and allow access to archived tissue specimens to perform additional biomarker 
testing. 
5) Precise molecular testing classification. Biomarkers, both present and absent, are recorded 
along with temporal association with treatment, tissue location, testing laboratory, testing 
details, and test version (see Figure 1A and 1B). This allows for the grouping of patients who 
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have received similar testing and can help determine results that may otherwise be less certain 
due to various factors. Newer testing techniques can be easily introduced to identify benefit. 
 
Figure 1. The Master Observational Trial (MOT) 
(A) The Molecular Classification Matrix. This is a graphical representation of the manner that the MOT classifies biomarker testing (this example examines 
a specific region of DNA). Testing methods are broken into technology (rows) and then are further subdivided into the general method that the given 
technology is applied (columns).  
(B) Laboratory test details: versions and tissue origin. Biomarker testing is initially categorized using the Molecular Classification Matrix (Figure 1A). 
Each specific technology and method (e.g., next-generation sequencing or NGS) is further broken down into a subcategory (i.e., whole exome sequencing), 
and then laboratories are grouped by those using similar analysis instrumentation and techniques on similar tissue. Versions of tests are also collected to 
allow for distinction between evolving technology.  
(C) Master Observational Trial Overview. This shows the structure of the MOT. Patients are broadly accepted into the trial along with diagnosis and 
staging (disease extent) information and informed consent. Biomarker testing results (both positive and negative) are collected and classified using methods 
shown in Figures 1A and 1B. High level outcomes are collected in connection with each line of therapy. All the information is tied together in a prospective 
observational registry using standardized reporting methods and metrics.  
(D) Interconnectivity and modularity of MOT design. All data collected is sorted and organized to allow for comparison and analysis of any testing or 
treatment method in combination or series. The evolution of data collected in the MOT starts with genomic (and other -omic) data, and then, as technology 
and availability progress, additional molecular testing methods are included. Novel molecular testing can be introduced, creating different arms (diagnostic 
modules). All diagnostic data is tied to treatments both standard and those not part of established compendia, combination therapies, or sequenced 
therapies (therapeutic modules). The prospective nature and precise molecular characterization allow for identification of specific subgroups of patients who 
can participate in interventional clinical trials that are directly related to or external to the MOT.  
Abbreviations: FISH – fluorescent in situ hybridization; IHC – immunohistochemistry; PCR – polymerase chain reaction. 
 
6) Standardized clinical data elements. The broad collection of data across multiple lines of 
therapy needs to have at least essential core data elements collected. Core elements need to 
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be robust enough to answer multiple questions and are likely going to be substantially different 
for different fields of medicine (see Figure 1C).  
7) Longitudinal data collection. By collecting key information on each phase of a patient’s 
journey from diagnosis to disease resolution or death, broader understanding of complex 
interactions can be explored. This longitudinal approach is necessary to give real-world context 
to knowledge gained from traditional trial data.  
8) Modular trial design (internal to protocol). Although data is observational, there needs to be 
a broad understanding of what types of patients should be included in the trial. This may be 
through focusing on certain types of testing or classes of treatments (see Figure 1D).  
9) Seamless integration with interventional trials or RWD (external to protocol). Attaching 
interventional trials, including single arm, master protocol, or randomized trials, inside the MOT 
structure allows for the answering of specific questions about new testing or therapy. This data 
can be directly integrated with the broad data collection that takes place within the MOT. 
Separate trials will have separate protocols, IRB approval, patient consent, and other 
components as necessary to be integrated into the MOT (see Figure 1D). 
10) Artificial intelligence and machine learning from multiple perspectives. MOTs will collect 
massive amounts of data. Artificial intelligence and advanced computing will be essential in 
turning raw data into actionable hypotheses. The higher quality and accessibility of the 
structured data in an MOT will provide improvement in adaptive algorithm development. 
Confirmation of findings through shared data access is valuable to remove potential bias. 
The Master Registry of Oncology Outcomes Associated with Testing and Treatment 
(ROOT) 
Within every trial type there is flexibility in design and implementation. MOTs are not any different. 
Areas that are likely going to see emphasis surround data collection needs, quality improvement, 
and/or broadening participation. The recently announced ROOT trial in oncology is one of the first 
examples of an MOT. Some of the modifications in general design and implementation that may or 
may not be present in other trials are as follows:  
1) Staged approach. MOTs are complex entities with many moving parts and competing interests. 
Rather than solve every complex problem that could be faced initially, ROOT started by 
focusing on two areas: 1) the unmet need of quality data to bridge the gap between clinical trials 
and unstructured RWD and 2) how this data could be collected using existing infrastructure. A 
core group of clinical leaders and cornerstone institutions agreed to work together to identify 
obstacles, propose solutions, and work toward building a national prospective oncology registry 
that could then advance globally. Several areas of caution were identified early on. These 
included concern for data collection for research purposes without IRB approval and patient 
consent, cumbersome collection methods, increased physician work, financial constraints, data 
sequestration, and data governance. An IRB-approved clinical protocol was developed 
alongside with general business framework, and cornerstone groups formally agreed to work 
together to find equitable solutions to the complex issues that would arise as the MOT evolved. 
2) Standardized clinical data elements. ROOT uses a slight modification of the core data 
elements tied to molecular data published through a multi-stakeholder effort (Conley et al., 
2017). The simpler data elements allow focused data collection of the most impactful data 
points on broader patient populations.  
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3) Data collection as part of current clinical flow. Data collection methods and forms mesh to 
current clinic personnel and physician workflow, thus minimizing impact on clinics, especially 
physician time. 
4) Shared data collection and protected physician time. Non-physician staff report data 
recorded in the medical record (e.g., treatments and dates), and physicians only report 
outcomes and medical decision making. The physician work has been designed to be part of a 
regular visit and to add negligibly to the time of that visit. Physician time to enroll patients must 
be protected in order to allow for broad patient accrual. 
5) Shared data access. ROOT will allow the scientific communities of participating institutions 
access to deidentified data placed in a server that will enable hypotheses generation and data 
review and publication. This broad access allows for greater research in order to help to 
advance precision medicine. To encourage sharing, institutions that are not contributing data 
may receive access through data delay, fees, or limited access. This will be determined by the 
participating institutions.  
6) Shared business models. To keep costs of operation low, and with the benefit of access of 
larger patient populations for research and clinical trials, data providers are asked to receive 
less than fair market value for collecting the elements that are required by the MOT. Then, as 
data is collected, if any commercial group wants access to the provided data for research 
purposes, net revenue (if any) will be shared by the institutions based on quantity and quality of 
provided data to allow continued participation. 
Discussion 
Challenges 
Broad physician support and patient numbers. MOTs can fill the gap that currently exists in 
precision medicine but only to the degree that these are supported by community and academic 
practices, both nationally and internationally. Areas of complexity that could hinder participation 
include data sharing, publication rights, intellectual property, financing and governance. Finding the 
right models that lead to formal contracts and allow for unification across institutions and borders 
could be challenging. Encouraging clinicians to report data when they are already busy could also 
create barriers. The use of physician extenders or trained coordinators can facilitate this process.  
Financing. The data in MOTs can benefit patients, physicians, biopharmaceutical companies, 
laboratories, manufacturers, payers, and regulators. Widespread support from groups who will 
receive benefit are needed to finance MOTs. The ambitious nature of the MOT may keep groups on 
the sidelines waiting to see traction before providing support. This could be ameliorated by 
providing early adopters quicker access to data than those who provide support later.  
Molecular data sharing. Laboratory data has many layers of information that could be used to help 
better understand precision medicine. Due to technological, competitive, and financial barriers, 
many groups have been reticent to provide data to outside groups. 
Sustainability. Turning precision medicine into personalized care is an ongoing effort. New 
technology and possible treatments are advancing faster than we are collecting the data to 
understand how to use these tools. We need long-term efforts to answer these questions. MOTs, 
like all other data collection efforts, need long-term support for success. 
Regulatory adoption. The FDA has used non-interventional data to support limited actions, but 
generally will not use RWD in regulatory decisions. The added quality of the MOT will likely 
increase the confidence to use RWD in some approvals. 
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Opportunities 
Precision medicine is complicated. No one group has the patient numbers and resources to collect 
the data necessary to fully advance the field. We need accessible, quality data on hundreds of 
thousands of patients, harboring the breadth of molecular alterations in order to develop 
scientifically rigorous analysis. Much of current retrospective RWD efforts are not of high enough 
quality to answer the complexity of questions. Interventional trials are time consuming and costly. 
Ultimately, the MOT provides a new vehicle to harness the power of RWD in order to unlock 
personalized medicine. It provides heretofore unavailable opportunities to yield information that has 
widespread benefits to patients, families, clinicians, regulators, payers, industry, researchers, and 
society.  
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